BIOTRICITY INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.0M | $13.8M | $12.1M | $9.6M | $7.7M | $3.4M | $1.4M | $398.2K |
| Cost of Revenue | $3.0M | $3.2M | $3.7M | $4.2M | $3.1M | $2.1M | $932.0K | $338.3K |
| Gross Profit | $12.9M | $10.6M | $8.4M | $5.4M | $4.6M | $1.3M | $485.8K | $59.9K |
| Gross Margin | 80.9% | 76.6% | 69.3% | 56.5% | 59.7% | 37.6% | 34.3% | 15.0% |
| Operating Expenses | ||||||||
| Research & Development | $2.8M | $2.2M | $2.6M | $3.2M | $2.7M | $2.1M | $1.4M | $1.3M |
| SG&A Expense | $8.5M | $10.9M | $14.6M | $17.6M | $18.6M | $12.6M | $10.1M | $7.3M |
| Operating Income | $1.7M | $-2.4M | $-8.8M | $-15.4M | $-16.7M | $-15.5M | $-11.1M | $-8.6M |
| Operating Margin | 10.6% | -17.8% | -73.2% | -159.9% | -218.8% | -457.7% | -780.6% | -2,157.7% |
| Interest Expense | — | — | $3.0M | $1.8M | $1.3M | — | — | — |
| Pretax Income | $-2.4M | $-8.4M | $-14.1M | $-18.7M | $-29.1M | $-15.5M | $-11.1M | $-8.6M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-2.4M | $-8.4M | $-14.1M | $-18.7M | $-29.1M | $-15.5M | $-11.1M | $-8.6M |
| Net Margin | -15.0% | -61.1% | -116.8% | -193.6% | -380.8% | -457.7% | -780.6% | -2,157.7% |
| EPS (Basic) | $-0.12 | $-0.56 | $-0.83 | $-1.13 | $-0.33 | $-0.22 | $-0.16 | $-0.13 |
| EPS (Diluted) | $-0.12 | $-0.56 | $-0.83 | $-1.13 | — | $-0.22 | $-0.16 | $-0.13 |
| Shares Outstanding (Basic) | 27.3M | 21.5M | 18.0M | 17.3M | 90.9M | 75.0M | 66.8M | 63.0M |
| Shares Outstanding (Diluted) | 27.3M | 21.5M | 18.0M | 17.3M | 90.9M | 75.0M | 66.8M | 63.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |